- Home
- RIGL vs SVRA Comparison
RIGL vs SVRA Comparison
Compare RIGL & SVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RIGL
- SVRA
- Stock Information
- Founded
- RIGL 1996
- SVRA N/A
- Country
- RIGL United States
- SVRA United States
- Employees
- RIGL N/A
- SVRA N/A
- Industry
- RIGL Biotechnology: Pharmaceutical Preparations
- SVRA Biotechnology: Pharmaceutical Preparations
- Sector
- RIGL Health Care
- SVRA Health Care
- Exchange
- RIGL Nasdaq
- SVRA Nasdaq
- Market Cap
- RIGL 486.4M
- SVRA 458.2M
- IPO Year
- RIGL 2000
- SVRA N/A
- Fundamental
- Price
- RIGL $20.09
- SVRA $2.69
- Analyst Decision
- RIGL Buy
- SVRA Buy
- Analyst Count
- RIGL 5
- SVRA 7
- Target Price
- RIGL $34.80
- SVRA $9.86
- AVG Volume (30 Days)
- RIGL 223.6K
- SVRA 609.7K
- Earning Date
- RIGL 03-04-2025
- SVRA 03-06-2025
- Dividend Yield
- RIGL N/A
- SVRA N/A
- EPS Growth
- RIGL N/A
- SVRA N/A
- EPS
- RIGL 0.22
- SVRA N/A
- Revenue
- RIGL $157,374,000.00
- SVRA N/A
- Revenue This Year
- RIGL $51.34
- SVRA N/A
- Revenue Next Year
- RIGL $15.75
- SVRA N/A
- P/E Ratio
- RIGL $91.32
- SVRA N/A
- Revenue Growth
- RIGL 21.65
- SVRA N/A
- 52 Week Low
- RIGL $7.48
- SVRA $2.59
- 52 Week High
- RIGL $29.82
- SVRA $5.70
- Technical
- Relative Strength Index (RSI)
- RIGL 45.75
- SVRA 40.81
- Support Level
- RIGL $20.00
- SVRA $2.65
- Resistance Level
- RIGL $21.93
- SVRA $2.91
- Average True Range (ATR)
- RIGL 1.30
- SVRA 0.11
- MACD
- RIGL -0.27
- SVRA 0.01
- Stochastic Oscillator
- RIGL 2.01
- SVRA 23.08
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
About SVRA Savara Inc.
Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.